[An antitumor osteotropic agent based on tumor necrosis factor]

Biomed Khim. 2015 Sep-Oct;61(5):652-6. doi: 10.18097/PBMC20156105652.
[Article in Russian]

Abstract

A novel drug for treatment of bone metastases based on human recombinant tumor necrosis factor (TNF-alpha) has been designed. The drug is a molecular structure containing yeast double-stranded ribonucleic acid (dsRNA) covered by the conjugate of polyanion dextran with TNF-alpha and bisphosphonate, alendronic acid. The structure is characterized by the combination of substances possessing antitumor activity (TNF-alpha, dsRNA) and a vector molecule (bisphosphonate) providing tropism to hydroxyapatite, the main mineral component of the bone tissue matrix. The conjugation conditions were optimized and the conjugates of TNF-alpha and alendronic acid with dextran were synthesized. Molecular structures were obtained by self-assembly, and the resulting complexes were separated by gel filtration on Sepharose CL-6B. The electrophoretic analysis method revealed decreased mobility of dsRNA in the complex with the conjugate as compared to the mobility of the original dsRNA. This confirms formation of the designed structures. Transmission electron microscopy confirmed the presence of particles with sizes of 30-40 nm in the drug. Evaluation by the sorption/desorption method showed a higher affinity of TNF-alpha conjugates to hydroxyapatite as compared to the original TNF-alpha molecules (from 1.0 to 1.8 mol/L vs. 0.3 mol/L of potassium phosphate buffer for desorption, respectively).

Razrabotan dizaĭn preparata dlia lecheniia kostnykh metastazov na osnove rekombinantnogo faktora nekroza opukholeĭ al'fa (FNO-al'fa) cheloveka. Preparat predstavliaet soboĭ molekuliarnuiu konstruktsiiu, soderzhashchuiu drozhzhevuiu dvuspiral'nuiu ribonukleinovuiu kislotu (dsRNK), pokrytuiu obolochkoĭ iz kon"iugata polianiona dekstrana s FNO-al'fa i bisfosfonatom (bifosfonatom) alendronovoĭ kislotoĭ. Osobennost'iu konstruktsii iavliaetsia sochetanie v odnoĭ strukture veshchestv, obladaiushchikh protivoopukholevoĭ aktivnost'iu (FNO-al'fa, dsRNK), i vektornoĭ molekuly (bisfosfonat), kotoraia obespechivaet tropnost' k gidroksiapatitu – osnovnomu mineral'nomu komponentu matriksa kostnoĭ tkani. Otrabotany usloviia kon"iugirovaniia i sintezirovany kon"iugaty FNO-al'fa i alendronovoĭ kisloty s dekstranom. Molekuliarnye konstruktsii poluchali metodom samosborki, obrazovavshiesia kompleksy otdeliali gel'-fil'tratsieĭ na sefaroze CL-6B. Élektroforeticheskiĭ analiz pokazal snizhenie podvizhnosti dsRNK v komplekse s kon"iugatom po sravneniiu s podvizhnost'iu iskhodnoĭ dsRNK, chto podtverzhdaet fakt obrazovaniia konstruktsiĭ. Metodom prosvechivaiushcheĭ élektronnoĭ mikroskopii podtverzhdeno nalichie v preparate chastits s razmerami poriadka 30-40 nm. Otsenka metodom sorbtsii/desorbtsii pokazala bolee vysokoe srodstvo kon"iugatov FNO-al'fa k gidroksiapatitu po sravneniiu s iskhodnymi molekulami FNO-al'fa (1,0-1,8 mol'/l protiv 0,3 mol'/l kaliĭ-fosfatnogo bufera, dlia desorbtsii, sootvetstvenno).

Keywords: alendronic acid; nanoparticles; tumor necrosis factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alendronate / chemistry*
  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Bone Neoplasms
  • Cell Line
  • Cell Survival / drug effects
  • DNA / chemistry*
  • Dextrans / chemistry*
  • Durapatite / chemistry
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Humans
  • Mice
  • Molecular Structure
  • Molecular Targeted Therapy
  • Nanoparticles / chemistry*
  • Nanoparticles / ultrastructure
  • Particle Size
  • Tumor Necrosis Factor-alpha / chemistry
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Antineoplastic Agents
  • Dextrans
  • Tumor Necrosis Factor-alpha
  • DNA
  • Durapatite
  • Alendronate